Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neumora Therapeutics, Inc. - Common Stock (NQ:NMRA)

2.590 -0.100 (-3.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neumora Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study
NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia 
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Analyst Expectations for Neumora Therapeutics's Future
 
Via Benzinga
Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Neumora Therapeutics to Participate in Upcoming Conferences in November
From Neumora Therapeutics, Inc.
Via GlobeNewswire
PagerDuty, John Wiley & Sons, Ventyx Biosciences And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Topics Stocks
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023
 
Via Benzinga
Why Neumora Therapeutics Analysts Are Bullish About Major Depressive Disorder Drug
Shares of Neumora Therapeutics Inc (NASDAQ: NMRA) were trading lower on Tuesday, a month after the company announced its IPO on the NASDAQ exchange. 
Via Benzinga
Topics Initial Public Offering
Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development
Dr. Lenz brings 20 years of neuroscience drug development expertise, with deep experience implementing successful clinical programs to support the development of novel medicines 
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Specialty Asian Grocer Maison Solutions Opens For Trading
Following a couple of high-profile trading debuts, the IPO market slowed down again. There was only one public offering of note this week, with California-based specialty Asian grocer Maison Solutions... 
Via Talk Markets
Topics Initial Public Offering
Why Intelligent Bio Solutions Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers AERWINS Technologies Inc. (NASDAQ: AWIN) shares climbed 86.1% to $0.2248 after the company said it is considering strategic alternatives for its non-core operations. 
Via Benzinga
Ticking Time Bombs: 3 New Stocks to Dump Before the Damage Is Done (IPO)
The IPO market is still far from being as hot as it was in 2021, and these three recently listed stocks are solid proof of that. 
Via InvestorPlace
Topics Initial Public Offering
Jabil, Chico's FAS And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mixed, with the Dow Jones gaining around 30 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Why Shares of Neumora Therapeutics Slumped This Week
The clinical-stage biotech just had its IPO last week. 
Via The Motley Fool
Topics Initial Public Offering
Why Gorilla Technology Group Shares Are Trading Lower By 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 104.5% to $0.1916. 
Via Benzinga
SoftBank-Owned Arm Jumps 20% In Market Debut
British chip designer Arm made its public debut on Thursday, with the shares jumping 10% right as the stock opened for trading. Arm's was the most high-profile Nasdaq IPO in the last few years, with... 
Via Talk Markets
Topics Initial Public Offering
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.